FT
BIVV

Fiduciary Trust’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Fiduciary Trust’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,220
Closed -$133K – 530
2017
Q2 		$133K Buy
+2,220
New +$126K ﹤0.01% 493

Other funds holding BIVV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fiduciary Trust's BIVV Position: Q3 2017 in Review

Fiduciary Trust sold out of Bioverativ Inc. Common Stock (BIVV) in Q3 2017, closing a stake of 2,220 shares — an estimated $133K sold.

Fiduciary Trust first reported a position in BIVV in Q2 2017 and held it in 1 quarter. The position peaked at $133K in Q2 2017. 446 funds tracked by Wall St. Rank hold BIVV as of Q3 2017.

  • Fiduciary Trust reported no remaining Bioverativ Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Fiduciary Trust sold 2,220 Bioverativ Inc. Common Stock shares in Q3 2017, an estimated $133K.
  • Fiduciary Trust first reported a position in Bioverativ Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • Fiduciary Trust's Bioverativ Inc. Common Stock position peaked at $133K in Q2 2017.
  • 446 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q3 2017.

Based on Fiduciary Trust's 13F filing for Q3 2017, filed 2 Nov 2017.